Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction
<p>Abstract</p> <p>Background</p> <p>The epidermal growth factor receptor (EGFR) inhibitor, gefitinib, has been reported to successfully treat advanced non-small cell lung cancer patients with genetic mutations in EGFR. The aim of this study was to investigate the exist...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2012-01-01
|
| Series: | World Journal of Surgical Oncology |
| Subjects: | |
| Online Access: | http://www.wjso.com/content/10/1/14 |